News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Schering AG (SHR) And Biogen Idec, Inc. (Massachusetts) (BIIB) Announce Start Of The ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin



10/5/2006 10:51:55 AM

BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Schering AG, Germany (FSE:SCH) (NYSE:SHR) and Biogen Idec Inc. (NASDAQ:BIIB) today announced the start of Zevalin (Ibritumomab Tiuxetan) in Aggressive Lymphoma (ZEAL), a Phase III, international multi-center clinical trial. Approximately 400 patients will be enrolled in the trial.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES